AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24041309 — intervention group
Group type: COMPARATOR
Intervention: No questionnaire
Number of subjects: 60000
Study 21443986 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-500 (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin)
Number of subjects: 1002
Study 21443986 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-1,000 (1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin)
Number of subjects: 1002
Study 21443986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 19577483 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy group (28 g/day textured soy flour for 8 weeks)
Number of subjects: 40
Study 19577483 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet without soy)
Number of subjects: 40
Study 21842299 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide-impregnated gauze
Number of subjects: 38
Study 21842299 — intervention group
Group type: COMPARATOR
Intervention: Plain gauze (control)
Number of subjects: 38
Study 16288151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy‐based Basic Life Support (SEBLS) program
Number of subjects: 38
Study 12860500 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/d
Number of subjects: 0
Study 12860500 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 0
Study 12860500 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (limited to responders)
Number of subjects: 0
Study 12860500 — intervention group
Group type: COMPARATOR
Intervention: No pharmacologic treatment (Control)
Number of subjects: 0
Study 9583728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with recombinant interferon
Number of subjects: 68
Study 9583728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with leukocyte interferon
Number of subjects: 68
Study 9583728 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide without interferon
Number of subjects: 68
Study 9583728 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-treatment S-VEGF (>527 pg/ml)
Number of subjects: 68
Study 9583728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-treatment S-VEGF (n = 17, 25% of all patients)
Number of subjects: 68
Study 7661070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide
Number of subjects: 23
Study 7661070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2573208 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg q12h
Number of subjects: 0
Study 2573208 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg q6h or q12h
Number of subjects: 0
Study 1275217 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative haemodilution with Dextran 60
Number of subjects: 0
Study 1275217 — intervention group
Group type: COMPARATOR
Intervention: Preoperative haemodilution with Dextran 40
Number of subjects: 0
Study 12297808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 10 days
Number of subjects: 11000
Study 12297808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 11000
Study 31045789 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block (SPB) with 20 ml of 0.375% ropivacaine
Number of subjects: 50
Study 31045789 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block (SPB)
Number of subjects: 50
Study 31045789 — intervention group
Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 50
Study 31045789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 29463119 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study 26573217 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen (30/50mg/kg)
Number of subjects: 25
Study 26573217 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Number of subjects: 25
Study 26573217 — intervention group
Group type: COMPARATOR
Intervention: Historical Control (HC)
Number of subjects: 25
Study 24502880 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 >1800 ng/L
Number of subjects: 1151
Study 24502880 — intervention group
Group type: COMPARATOR
Intervention: GDF-15 <1200 ng/L
Number of subjects: 1151
Study 22410599 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term life review (60 minutes, twice a week)
Number of subjects: 32
Study 20453155 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation (watching video clips showing specific movements and strategies to circumvent FOG episodes)
Number of subjects: 20
Study 20453155 — intervention group
Group type: COMPARATOR
Intervention: Landscape (watching video clips of static pictures showing different landscapes)
Number of subjects: 20
Study 20453155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent identical physical therapy training (3 sessions a week for 4 weeks)
Number of subjects: 20
Study 18789901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigaptide (0.25-25 nmol/min)
Number of subjects: 27
Study 18789901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (5-20 microg/min)
Number of subjects: 27
Study 18789901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (30-300 pmol/min)
Number of subjects: 27
Study 18789901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2-8 microg/min)
Number of subjects: 27
Study 15744332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu298Asp polymorphism carriers (298Asp allele)
Number of subjects: 294
Study 15744332 — intervention group
Group type: COMPARATOR
Intervention: Glu/Glu homozygotes
Number of subjects: 294
Study 11926939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 74
Study 11926939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9461369 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (0.25 ml Ventolin 0.5%)
Number of subjects: 52
Study 9461369 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide (0.25 ml Atrovent 0.025%)
Number of subjects: 52
Study 9461369 — intervention group
Group type: COMPARATOR
Intervention: none (control group: patients who did not develop BPD)
Number of subjects: 52
Study 9461369 — intervention group
Group type: COMPARATOR
Intervention: none (routine administration of bronchodilators)
Number of subjects: 52
Study 9097801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic nevus syndrome
Number of subjects: 162
Study 9097801 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 162
Study 2651951 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 7
Study 2651951 — intervention group
Group type: COMPARATOR
Intervention: Slow channel calcium entry blocker (Ca antagonist)
Number of subjects: 7
Study 1268475 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0
Study 1268475 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and antrectomy
Number of subjects: 0
Study 1268475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple abnormalities present
Number of subjects: 0
Study 31596110 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP60 (trained group at 60% of the maximal inspiratory pressure)
Number of subjects: 30
Study 31596110 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP (trained group at critical inspiratory pressure)
Number of subjects: 30
Study 31596110 — intervention group
Group type: COMPARATOR
Intervention: SHAM (sham-trained group)
Number of subjects: 30
Study 28585868 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 90
Study 28585868 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 25325342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (started at post-operative 3rd hour, chewed every 4 hours for 30 minutes)
Number of subjects: 137
Study 25325342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 137
Study 25325342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 137
Study 23127158 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized radiofrequency heat (RFH) therapy
Number of subjects: 0
Study 23127158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20952228 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRO plus coronoidotomy
Number of subjects: 56
Study 20952228 — intervention group
Group type: COMPARATOR
Intervention: Simple IVRO
Number of subjects: 56
Study 19523421 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAD‐PBCA‐NPs
Number of subjects: 108
Study 19523421 — intervention group
Group type: COMPARATOR
Intervention: DHAD injection
Number of subjects: 108
Study 17000418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early persistent middle ear effusion (MEE)
Number of subjects: 226
Study 17000418 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without early MEE)
Number of subjects: 226
Study 12749489 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 0
Study 12749489 — intervention group
Group type: COMPARATOR
Intervention: Control (no ITNs)
Number of subjects: 0
Study 11015815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d
Number of subjects: 206
Study 11015815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 206
Study 11015815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 206
Study 11015815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 11015815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 206
Study 8783218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction of the left visual field
Number of subjects: 22
Study 8783218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction of the right visual field
Number of subjects: 22
Study 8783218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction
Number of subjects: 22
Study 8783218 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual field left hemisphere P200 reduction
Number of subjects: 22
Study 1740583 — intervention group
Group type: EXPERIMENTAL
Intervention: Honeybee venom immunotherapy (VIT)
Number of subjects: 205
Study 1740583 — intervention group
Group type: COMPARATOR
Intervention: Yellow jacket venom immunotherapy (VIT)
Number of subjects: 205
Study 6326999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy (4200 rad)
Number of subjects: 101
Study 6326999 — intervention group
Group type: COMPARATOR
Intervention: Combined radiotherapy and chemotherapy (3000 rad)
Number of subjects: 101
Study 6326999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy
Number of subjects: 101
Study 31902373 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole raw Gala apples (approximately 200 g)
Number of subjects: 26
Study 31902373 — intervention group
Group type: COMPARATOR
Intervention: Control (without apples)
Number of subjects: 26
Study 31150780 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo conditioning with instrumental control over treatment administration
Number of subjects: 87
Study 31150780 — intervention group
Group type: COMPARATOR
Intervention: Standard passive placebo conditioning without any control over treatment administration
Number of subjects: 87
Study 31150780 — intervention group
Group type: COMPARATOR
Intervention: Natural history control group with no conditioning
Number of subjects: 87
Study 29340524 — intervention group
Group type: EXPERIMENTAL
Intervention: FFC group (400 µs)
Number of subjects: 72
Study 29340524 — intervention group
Group type: EXPERIMENTAL
Intervention: SSP group (50 µs pulse)
Number of subjects: 72
Study 29340524 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP group (100 µs pulse)
Number of subjects: 72
Study 29340524 — intervention group
Group type: EXPERIMENTAL
Intervention: SP group (300 µs pulse)
Number of subjects: 72
Study 29340524 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (no treatment)
Number of subjects: 72
Study 29340524 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (12 teeth without carious lesion)
Number of subjects: 72
Study 27111078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral nonvascularized autograft and periosteal repair
Number of subjects: 4
Study 27111078 — intervention group
Group type: COMPARATOR
Intervention: Control group (other limb-salvage or amputation procedures)
Number of subjects: 4
Study 24673044 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular points group (magnetic-ball sticking therapy)
Number of subjects: 90
Study 24673044 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 90
Study 22337561 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 27
Study 22337561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20590745 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 4555
Study 16633709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 60
Study 16633709 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMF
Number of subjects: 60
Study 16633709 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid + anesthetic agent injection
Number of subjects: 60
Study 16257793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 331
Study 16257793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 331
Study 16257793 — intervention group
Group type: COMPARATOR
Intervention: Control group of a randomised trial of epoetin alfa
Number of subjects: 331
Study 11879235 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin omega
Number of subjects: 38
Study 11879235 — intervention group
Group type: COMPARATOR
Intervention: epoetin alfa
Number of subjects: 38
Study 10397617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dissolving reference formulation
Number of subjects: 480
Study 10397617 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical slow dissolving test formulation
Number of subjects: 480
Study 10397617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmax/AUCt measure
Number of subjects: 480
Study 9097709 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 staining
Number of subjects: 120
Study 9097709 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA staining
Number of subjects: 120
Study 9097709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 staining
Number of subjects: 120
Study 9097709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher staining scores for p53, PCNA, and Ki67
Number of subjects: 120
Study 1915135 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls
Number of subjects: 26
Study 1915135 — intervention group
Group type: COMPARATOR
Intervention: Conventional diazepam
Number of subjects: 26
Study 6353428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%) ophthalmic solution
Number of subjects: 38
Study 6353428 — intervention group
Group type: COMPARATOR
Intervention: Naphazoline (0.04%) solution
Number of subjects: 38
Study 31469749 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional ablative CO2 laser treatment
Number of subjects: 29
Study 29665830 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus a brief GOH-based intervention (CT-GOHT)
Number of subjects: 40
Study 29665830 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 40
Study 29044223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transcranial direct current stimulation (tDCS) over sensorimotor areas
Number of subjects: 26
Study 26199142 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth remote monitoring with paired glucose testing and asynchronous virtual visits
Number of subjects: 90
Study 26199142 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 26199142 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth remote monitoring
Number of subjects: 90
Study 23900369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 121
Study 23900369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 121
Study 23900369 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 121
Study 23900369 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 121
Study 23900369 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 121
Study 19949848 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing Opportunities for People with AIDS (HOPWA) rental assistance
Number of subjects: 630
Study 19949848 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 630
Study 18262140 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Number of subjects: 48
Study 18262140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16606646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2 g/day
Number of subjects: 230
Study 16606646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 15005736 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific allergy vaccination (SAV)
Number of subjects: 0
Study 15005736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11153633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (n = 15), cooled to 32 to 33 degrees C after administration of vecuronium, midazolam, and buprenorphine.
Number of subjects: 26
Study 11153633 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (n = 11), body temperature controlled at 36 to 37 degrees C with the same treatment as hypothermic group.
Number of subjects: 26
Study 9100038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 to 600 mg/d plus prednisone 2.5 mg/d
Number of subjects: 20
Study 9100038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 8103146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' preferences for withdrawing life support
Number of subjects: 862
Study 8103146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' decision-making biases
Number of subjects: 862
Study 2994436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 85
Study 2994436 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 85
Study 3219853 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380Ag
Number of subjects: 884
Study 3219853 — intervention group
Group type: COMPARATOR
Intervention: Multiload Cu 375
Number of subjects: 884
Study 28724338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT (iCBT)
Number of subjects: 140
Study 28724338 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 140
Study 27476798 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department (ED) care
Number of subjects: 1150
Study 27476798 — intervention group
Group type: COMPARATOR
Intervention: General Practitioner (GP) care
Number of subjects: 1150
Study 23900984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol using intermittent bolus technique
Number of subjects: 702
Study 23900984 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol using continuous infusion
Number of subjects: 702
Study 24336997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) program
Number of subjects: 0
Study 21050553 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dinoprostone suppository and ethacridine
Number of subjects: 96
Study 21050553 — intervention group
Group type: COMPARATOR
Intervention: Ethacridine alone
Number of subjects: 96
Study 18437172 — intervention group
Group type: EXPERIMENTAL
Intervention: Various compounds targeting MAPK pathway
Number of subjects: 0
Study 16628069 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 80 mmol/day
Number of subjects: 60
Study 16628069 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 60
Study 15518608 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 3
Study 15518608 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with verapamil
Number of subjects: 3
Study 15518608 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin with mibefradil
Number of subjects: 3
Study 15518608 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin with itraconazole
Number of subjects: 3
Study 15518608 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 statins with clarithromycin
Number of subjects: 3
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grade vulvar intraepithelial neoplasia
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grade vaginal intraepithelial neoplasia
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grade penile intraepithelial neoplasia
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade intraepithelial neoplasia
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive vulvar carcinoma
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive vaginal carcinoma
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive penile carcinoma
Number of subjects: 423
Study 10863176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intraepithelial neoplasias
Number of subjects: 423
Study 9504888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 12
Study 9504888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12